Q2 2017 TG Therapeutics Inc Earnings Call

9/8/2017 8:30

Llamada en conferencia TG Therapeutics Inc

TG Therapeutics Inc Conference call or earnings call will be held on 09-ago-2017
During the earnings conference call’s session, TG Therapeutics Inc will provide updated information and financial performance report status.
In order to join the earning call, dial the conference’s bridge and key in the PIN code. Contact TG Therapeutics Inc for this information
More and more companies choose to conduct their earnings calls through conference calls and online meetings and it’s important to keep up to date with all relevant information.
Need a conference calls service solution? Try QCONF conferencing today, Sign up now and get 5 free conference calls (no credit card required)
Is this is your first earnings call? Check out Nasdaq guide for how to read an earnings report?
We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B-lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has pre-clinical programs seeking to develop IRAK4 (interleukin-1 receptor-associated kinase 4) inhibitors and anti-PD-L1 and anti-GITR antibodies.    
Leer más Llamada en conferencia

TG Therapeutics Inc (TGTX)

3 Columbus Circle, New York New York 10019, United States